Drug trial led by Cincinnati researchers gains national media attention

Dr. Evan Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinnati, is leading clinical trials for a new drug candidate (REGN727) that may do a better job of lowering cholesterol than statins, and with fewer side effects. The New York Times and ABC News took notice last month.

Dr. Evan Stein

Study results were published in a recent issue of The New England Journal of Medicine.

“About 5 to 10 percent of people can’t tolerate statins at all, and more can’t tolerate higher doses,” said Dr. Evan A. Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinnati and lead author of the drug trials. “It’s still early in development, but for them this is potentially a most promising alternative.”

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

NanoLogix developing rapid test for Ebola virus (video) | WYTV33 Youngstown, October 21, 2014

Analytic, a partnership of Anatrace and Microlytic: enabling membrane protein research | PR Web, October 21, 2014

Quasar Energy Group uses organic waste to produce renewable energy | Todays Energy Solutions, October 21, 2014

Frank Samuel, President of VentureOhio and former BioOhio President dies in auto accident | Geauga County Maple Leaf, October 21, 2014

Milo Biotechnology’s follistatin gene therapy increases function in Becker Muscular Dystrophy patients | PR Newswire, October 20, 2014

OSU Wexner Medical Center study: new implantable device to control heart failure shows promising results | Todays Medical Developments, October 17, 2014

Assurex Health gets $6M funding for clinical trial related to patients with depression or schizophrenia | Cincinnati Business Courier, October 17, 2014

University of Cincinnati lands grant to attack hepatitis C among needle users in 20 counties | WCPO9 Cincinnati, October 16, 2014

Control Bionics interview, developing technology that enables individuals with debilitating conditions to communicate | The Clermont Sun, October 16, 2014

BioOhio member Oralectrics spinout Zumby opens crowdfunding campaign | Cleveland.com, October 16, 2014

Ohio State sophomore Peeyush Shrivastava of Genetesis named a finalist in $5M 43North business plan competition | Columbus Business First, October 16, 2014

Navidea hires Rick Gonzalez as CEO from Spectrum Pharmaceuticals, replaces Michael Goldberg, Navidea’s lead investor | Columbus Business First, October 15, 2014

Health Care DataWorks’ Chief Data Scientist to present at healthcare conference sponsored by HIMSS Georgia Chapter | PR Web, October 15, 2014

FDA approves expanded use of Navidea’s Lymphoseek for lymphatic mapping in solid tumors | Business Wire, October 15, 2014

Crowdfunding launches today for Animal Oralectrics’ new medical device for dogs that fights oral bacteria while playing | PR Newswire, October 15, 2014

NanoLogix technology being configured for rapid Ebola and Enterovirus detection | Business Wire, October 14, 2014

Nanotronics Imaging releases nSPEC 3D, powerful microscope that captures 3D images at nanoscale, in lightning speed | Business Wire, October 14, 2014

Cincinnati Children’s Hospital Medical Center announces a new treatment designed to save more eyes from cancer | PR Newswire, October 14, 2014

Ischemia Care raises $1.9M for stroke detection technology | MedCity News, October 13, 2014

STERIS to acquire Synergy Health for $1.9 Billion in cash and stock | STERIS, October 13, 2014